BioMarin Launches Firdapse In Germany And The UK
This article was originally published in The Pink Sheet Daily
Executive Summary
Biomarin's fourth orphan product, amifampridine, launched for the symptomatic treatment of Lambert Eaton myasthenic syndrome.